RARE DISEASE
Giant cell tumor of bone
Giant cell tumor of bone
Giant cell tumor of bone
Synonyms: GCT of bone, Osteoclastoma
Synonyms: GCT of bone, Osteoclastoma
Synonyms: GCT of bone, Osteoclastoma
Drug discovery
1
drug
With orphan designation
Overview
Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm composed of mononuclear stromal cells and osteoclast-like giant cells. Typically arising in the epiphysis of long bones (e.g., distal femur, proximal tibia), it primarily affects skeletally mature individuals aged 20–40 years. While GCTB rarely metastasizes (1–3% to lungs), it causes significant bone destruction and has recurrence rates of 15–50% after treatment. Diagnosis relies on imaging (lytic lesions with "soap bubble" appearance) and histopathology [1][4][6][9].
Burden
Local destruction causes pathological fractures (10–30%) and joint dysfunction [4][6][12]
Recurrence: 25–50% after curettage; 5–15% after wide resection [3][9][16]
Economic/QoL impact: Multiple surgeries common (median 2 procedures); 10-year survival drops to 70% with malignant transformation [8][9][13]
Therapies
Surgical: Curettage with adjuvants (phenol, bone cement) ± preoperative denosumab (RANKL inhibitor) to reduce tumor size [3][8][10]. Wide resection reserved for complex cases (pelvis/spine) or recurrence [8][12]
Medical: Denosumab (FDA-approved) for unresectable/metastatic disease, though associated with rebound recurrence post-treatment [3][13][19]
Adjuncts: Embolization for sacral tumors; radiotherapy limited due to malignant transformation risk [5][8][12]
Categories: rare bone diseases, rare neoplastic diseases
Research Papers
1,872 drug discovery papers about Giant cell tumor of bone, with 3 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,872 drug discovery papers about Giant cell tumor of bone, with 3 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-14 | Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non-Randomized Comparative Interventional Study.
Giant cell tumor of bone (GCTB) is a rare, locally aggressive osteolytic neoplasm associated with a substantial risk of local recurrence and challenging surgical management. Denosumab, a monoclonal antibody, has emerged as a promising therapeutic option. This study evaluates the efficacy of denosumab as a neoadjuvant therapy in patients with Grade III GCTB, with particular emphasis on tumor recurrence, ossification, and surgical outcomes. In this prospective, non-randomized comparative interventional study, 34 adults with histologically confirmed Campanacci Grade III GCTB were enrolled and prospectively followed. Sixteen patients received neoadjuvant denosumab and 18 contemporaneous patients underwent surgery without neoadjuvant denosumab. Treatment allocation was based on routine clinical decision-making and patient-specific factors rather than randomization. During the 18-month follow-up period, local recurrence occurred in 2 of 16 patients (12.5%) in the denosumab intervention group and in 8 of 18 patients (44.4%) in the comparison group (p = 0.063). Radiological ossification was observed in all patients in the denosumab group and in none of the patients in the comparison group. Curettage and cementation were performed in 14 patients (87.5%) in the intervention group and 12 patients (66.7%) in the comparison group; this difference was not statistically significant (p = 0.233). Qualitative histopathological assessment of available specimens from denosumab-treated patients demonstrated marked depletion or disappearance of osteoclast-like giant cells, accompanied by treatment-related changes including new bone formation, fibrosis, and hemorrhage. In this study, neoadjuvant denosumab was associated with complete radiological ossification, qualitative histopathological changes characterized by marked depletion of osteoclast-like giant cells, and numerically lower observed local recurrence and greater use of curettage and cementation, although the latter two between-group differences were not statistically significant.
2026-08-14 | Extensive Giant Cell Tumor Involving Entire Tibia with Talar Extension and Pulmonary Metastases: Successful Limb Preservation with Denosumab and Angioembolization.
Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm with a recognized propensity for recurrence and occasional pulmonary metastasis. Diffuse involvement of an entire long bone is exceptionally rare. A 29-year-old female with four previous surgeries for recurrent distal tibial giant cell tumor presented with extensive involvement of the entire tibia, talar extension, and pulmonary metastases. Histopathology and H3.3G34W immunostaining confirmed the diagnosis. Limb salvage reconstruction was not feasible and amputation was declined. Selective angioembolization followed by denosumab 120 mg monthly for 6 months resulted in significant clinical improvement and disease stabilization. At 24 months, the patient remained independently ambulatory with stable local and pulmonary disease. Combined angioembolization and denosumab may provide durable disease control and limb preservation in selected patients with extensive unresectable GCTB.
2026-08-07 | Intralesional resection and autologous fibular graft reconstruction for a giant cell tumor of the fourth metacarpal with a secondary aneurysmal bone cyst: a case report
Introduction and importance: Giant cell tumor (GCT) of bone rarely involves the metacarpal bones. Secondary aneurysmal bone cyst (ABC) changes arising in association with GCT create distinct diagnostic and therapeutic challenges in this uncommon skeletal location. Case presentation: A 21-year-old right-hand-dominant female presented with progressive right fourth metacarpal pain and swelling following minor trauma. Radiographs and magnetic resonance imaging (MRI) demonstrated an expansile osteolytic lesion with cortical thinning and internal fluid–fluid levels suggesting GCT with secondary ABC changes. Preoperative chest radiography showed no evidence of pulmonary metastasis. Intralesional resection was performed while preserving the metacarpal head articular surface. Biological reconstruction was achieved using a non-vascularized autologous fibular graft stabilized with Kirschner wires. Histopathological examination confirmed GCT associated with secondary ABC changes and excluded telangiectatic osteosarcoma. At the 6-month follow-up, the patient demonstrated satisfactory graft incorporation, excellent hand function, and no evidence of local recurrence or pulmonary metastasis. Clinical discussion: Hand GCTs exhibit more aggressive behavior and higher recurrence rates than those in conventional skeletal locations. Differentiating secondary ABC from primary ABC and from telangiectatic osteosarcoma is essential, as treatment strategies and oncological implications differ significantly. Conclusion: Intralesional resection followed by biological reconstruction using a non-vascularized autologous fibular graft preserves hand function while achieving satisfactory early local disease control in selected patients.
2026-07-10 | Short-term Functional Outcomes of Shoulder Girdle Limb Salvage in Primary Bone Tumors: A 2-year Follow-up Study.
The shoulder girdle, encompassing the proximal humerus, scapula, lateral third of the clavicle, and surrounding soft tissues, is the third most frequent site for bone tumors. The proximal humerus is the most commonly affected area, followed by the scapula and clavicle. Managing malignant or aggressive benign bone tumors in this region is particularly challenging due to the proximity to vital neurovascular structures and the need to maintain both stability and dexterity in the shoulder. While traditional treatment often involved extensive resections, contemporary limb salvage techniques focus on preserving function while ensuring effective tumor control. This prospective study included 18 patients who underwent various limb salvage procedures at the Department of Orthopaedics, Vydehi Institute of Medical Sciences and Research Centre in Bengaluru between 2012 and 2019, with a minimum follow-up of 2 years. Diagnosis and staging were performed using imaging modalities and core needle biopsies, with musculoskeletal tumors staged according to the Enneking System. Functional outcomes were assessed using the Musculoskeletal Tumor Society Rating Scale (MSTS). Surgical techniques varied and included endoprosthetic reconstruction, arthrodesis with fibular grafting and plating, and plate fixation with primary shortening. Among the 18 patients, the majority (61%) had giant cell tumors, followed by aneurysmal bone cysts (17%), chondrosarcoma (11%), and osteosarcoma (11%). Functional outcomes, as measured by the MSTS, showed a 75% satisfactory rate. The study population was composed of 55.56% males and 44.44% females. Key parameters evaluated included pain, functional activity, hand positioning, dexterity, lifting ability, and emotional acceptance. Limb salvage surgery for primary bone tumors of the shoulder girdle offers favorable functional outcomes and represents a viable alternative to amputation. Modern reconstruction techniques, such as endoprosthetic reconstruction and fibular grafting with plating, achieve satisfactory results in both function and appearance. The MSTS scoring system is an effective tool for assessing postoperative functional status, and there is a growing preference for less aggressive surgical techniques that preserve limb function while ensuring tumor control.
2026-07-10 | A Rare Case of Giant Cell tumor of Bone in Distal Tibia.
Giant cell tumors of bone commonly seen in the distal femur, proximal tibia and distal radius and are seen in the age group of 20-40 years with female preponderance. Being close to the joint, the management is formidable, and there are no clinical, radiological or histological parameters to predict chances of recurrence or metastasis. Here, we present a rare case of giant cell tumor of the distal tibia treated successfully with no recurrence at the end of 4 years. A 33-year-old female presented with complaints of pain, swelling and decreased range of motion (ROM) at the left ankle joint for 6 weeks. On examination, we observed swelling and tenderness on left ankle joint with decreased ROM. X-rays and computed tomography revealed a well-defined expansile osteolytic lesion in the distal epiphysio-metaphyseal region of the left tibia without breach in the tibial cortex or ankle joint. Surgery by extensive curettage, adjuvants, cementation and prophylactic fixation was performed. Oral alendronate was started and continued for 24 months after surgery. The patient at 4-year follow-up is doing well, walking without pain, able to squat, having full ROM of the ankle joint with no signs of recurrence.
2026-08-14 | Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non-Randomized Comparative Interventional Study.
Giant cell tumor of bone (GCTB) is a rare, locally aggressive osteolytic neoplasm associated with a substantial risk of local recurrence and challenging surgical management. Denosumab, a monoclonal antibody, has emerged as a promising therapeutic option. This study evaluates the efficacy of denosumab as a neoadjuvant therapy in patients with Grade III GCTB, with particular emphasis on tumor recurrence, ossification, and surgical outcomes. In this prospective, non-randomized comparative interventional study, 34 adults with histologically confirmed Campanacci Grade III GCTB were enrolled and prospectively followed. Sixteen patients received neoadjuvant denosumab and 18 contemporaneous patients underwent surgery without neoadjuvant denosumab. Treatment allocation was based on routine clinical decision-making and patient-specific factors rather than randomization. During the 18-month follow-up period, local recurrence occurred in 2 of 16 patients (12.5%) in the denosumab intervention group and in 8 of 18 patients (44.4%) in the comparison group (p = 0.063). Radiological ossification was observed in all patients in the denosumab group and in none of the patients in the comparison group. Curettage and cementation were performed in 14 patients (87.5%) in the intervention group and 12 patients (66.7%) in the comparison group; this difference was not statistically significant (p = 0.233). Qualitative histopathological assessment of available specimens from denosumab-treated patients demonstrated marked depletion or disappearance of osteoclast-like giant cells, accompanied by treatment-related changes including new bone formation, fibrosis, and hemorrhage. In this study, neoadjuvant denosumab was associated with complete radiological ossification, qualitative histopathological changes characterized by marked depletion of osteoclast-like giant cells, and numerically lower observed local recurrence and greater use of curettage and cementation, although the latter two between-group differences were not statistically significant.
2026-08-14 | Extensive Giant Cell Tumor Involving Entire Tibia with Talar Extension and Pulmonary Metastases: Successful Limb Preservation with Denosumab and Angioembolization.
Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm with a recognized propensity for recurrence and occasional pulmonary metastasis. Diffuse involvement of an entire long bone is exceptionally rare. A 29-year-old female with four previous surgeries for recurrent distal tibial giant cell tumor presented with extensive involvement of the entire tibia, talar extension, and pulmonary metastases. Histopathology and H3.3G34W immunostaining confirmed the diagnosis. Limb salvage reconstruction was not feasible and amputation was declined. Selective angioembolization followed by denosumab 120 mg monthly for 6 months resulted in significant clinical improvement and disease stabilization. At 24 months, the patient remained independently ambulatory with stable local and pulmonary disease. Combined angioembolization and denosumab may provide durable disease control and limb preservation in selected patients with extensive unresectable GCTB.
2026-08-07 | Intralesional resection and autologous fibular graft reconstruction for a giant cell tumor of the fourth metacarpal with a secondary aneurysmal bone cyst: a case report
Introduction and importance: Giant cell tumor (GCT) of bone rarely involves the metacarpal bones. Secondary aneurysmal bone cyst (ABC) changes arising in association with GCT create distinct diagnostic and therapeutic challenges in this uncommon skeletal location. Case presentation: A 21-year-old right-hand-dominant female presented with progressive right fourth metacarpal pain and swelling following minor trauma. Radiographs and magnetic resonance imaging (MRI) demonstrated an expansile osteolytic lesion with cortical thinning and internal fluid–fluid levels suggesting GCT with secondary ABC changes. Preoperative chest radiography showed no evidence of pulmonary metastasis. Intralesional resection was performed while preserving the metacarpal head articular surface. Biological reconstruction was achieved using a non-vascularized autologous fibular graft stabilized with Kirschner wires. Histopathological examination confirmed GCT associated with secondary ABC changes and excluded telangiectatic osteosarcoma. At the 6-month follow-up, the patient demonstrated satisfactory graft incorporation, excellent hand function, and no evidence of local recurrence or pulmonary metastasis. Clinical discussion: Hand GCTs exhibit more aggressive behavior and higher recurrence rates than those in conventional skeletal locations. Differentiating secondary ABC from primary ABC and from telangiectatic osteosarcoma is essential, as treatment strategies and oncological implications differ significantly. Conclusion: Intralesional resection followed by biological reconstruction using a non-vascularized autologous fibular graft preserves hand function while achieving satisfactory early local disease control in selected patients.
2026-07-10 | Short-term Functional Outcomes of Shoulder Girdle Limb Salvage in Primary Bone Tumors: A 2-year Follow-up Study.
The shoulder girdle, encompassing the proximal humerus, scapula, lateral third of the clavicle, and surrounding soft tissues, is the third most frequent site for bone tumors. The proximal humerus is the most commonly affected area, followed by the scapula and clavicle. Managing malignant or aggressive benign bone tumors in this region is particularly challenging due to the proximity to vital neurovascular structures and the need to maintain both stability and dexterity in the shoulder. While traditional treatment often involved extensive resections, contemporary limb salvage techniques focus on preserving function while ensuring effective tumor control. This prospective study included 18 patients who underwent various limb salvage procedures at the Department of Orthopaedics, Vydehi Institute of Medical Sciences and Research Centre in Bengaluru between 2012 and 2019, with a minimum follow-up of 2 years. Diagnosis and staging were performed using imaging modalities and core needle biopsies, with musculoskeletal tumors staged according to the Enneking System. Functional outcomes were assessed using the Musculoskeletal Tumor Society Rating Scale (MSTS). Surgical techniques varied and included endoprosthetic reconstruction, arthrodesis with fibular grafting and plating, and plate fixation with primary shortening. Among the 18 patients, the majority (61%) had giant cell tumors, followed by aneurysmal bone cysts (17%), chondrosarcoma (11%), and osteosarcoma (11%). Functional outcomes, as measured by the MSTS, showed a 75% satisfactory rate. The study population was composed of 55.56% males and 44.44% females. Key parameters evaluated included pain, functional activity, hand positioning, dexterity, lifting ability, and emotional acceptance. Limb salvage surgery for primary bone tumors of the shoulder girdle offers favorable functional outcomes and represents a viable alternative to amputation. Modern reconstruction techniques, such as endoprosthetic reconstruction and fibular grafting with plating, achieve satisfactory results in both function and appearance. The MSTS scoring system is an effective tool for assessing postoperative functional status, and there is a growing preference for less aggressive surgical techniques that preserve limb function while ensuring tumor control.
2026-07-10 | A Rare Case of Giant Cell tumor of Bone in Distal Tibia.
Giant cell tumors of bone commonly seen in the distal femur, proximal tibia and distal radius and are seen in the age group of 20-40 years with female preponderance. Being close to the joint, the management is formidable, and there are no clinical, radiological or histological parameters to predict chances of recurrence or metastasis. Here, we present a rare case of giant cell tumor of the distal tibia treated successfully with no recurrence at the end of 4 years. A 33-year-old female presented with complaints of pain, swelling and decreased range of motion (ROM) at the left ankle joint for 6 weeks. On examination, we observed swelling and tenderness on left ankle joint with decreased ROM. X-rays and computed tomography revealed a well-defined expansile osteolytic lesion in the distal epiphysio-metaphyseal region of the left tibia without breach in the tibial cortex or ankle joint. Surgery by extensive curettage, adjuvants, cementation and prophylactic fixation was performed. Oral alendronate was started and continued for 24 months after surgery. The patient at 4-year follow-up is doing well, walking without pain, able to squat, having full ROM of the ankle joint with no signs of recurrence.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Giant cell tumor of bone, including 1 approved therapy.
1 orphan drug designation for Giant cell tumor of bone, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
denosumab [Xgeva] | antibodies | FDA | 2010-12-20 | 2013-06-13 | Amgen, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.